FDA Scales Back Domestic Inspections Due To Coronavirus
Agency Will Focus On Safety Of Regulated Products
After postponing foreign inspections, the US FDA has further decided to scale back domestic inspections due to the coronavirus outbreak.
You may also be interested in...
Specific guidance for ANDA sponsors on bioequivalence studies during the COVID-19 pandemic has been published by the US FDA.
Jubilant Life Sciences anticipates continued strong demand despite temporary logistics blips in India and expects to resume operations at its Nanjangud plant, currently shut down due to a few COVID-19 cases among employees, by mid-April. It is also evaluating the feasibility of manufacturing some of the APIs recently incentivized by the Indian government.
The US FDA is postponing “most foreign inspections” through April as a result of the coronavirus outbreak, because it will temporarily not be able to physically inspect foreign produced FDA-regulated products or manufacturers. However, inspections outside the US deemed as critical “will still be considered on a case-by-case basis.”